Health

Pfizer, BioNTech Report 80% Efficacy of Covid-19 Vaccine for Younger Children

None of the children had any serious side effects, the publication said.

“The above data on safety, immunogenicity and efficacy are encouraging, and we look forward to completing our submission to global regulators soon, in the hope that this vaccine will be available to younger children as soon as possible under regulatory authorization,” said Albert Buzzer. The CEO said in a statement.

Wallpaper: Pfizer and BioNTech originally asked the FDA to authorize their double firing Covid-19 regimen for children from 6 months to 5 years In February. Agency The meeting of the Advisory Committee was postponed Who is considering a vaccine for this population would prefer to wait for more data on the third dose. Pfizer tested a dose for children that was about one-tenth of that of adults. Two doses the size of a child in children 6 to 24 months of age developed immunity comparable to young adults who received two full doses. The same two pediatric doses did not produce similar immunity in children 2 to 5 years of age.

The companies collected data on three doses of their vaccine in 1,678 children who received the third vaccine at least two months after the second dose, the publication said. The Omicron was the dominant variant of Covid-19 circulating at the time.

At the end of April, Asked Moderna FDA Allow its dosed Covid-19 vaccine for the same age group. Late-stage clinical trials have shown that pediatric doses of its vaccines generated relative immunity in the youngest children as two full doses in the young.

However, the Moderna vaccine reduced symptomatic cases of Covid-19 by 43.7 percent in children 6 to 24 months of age and 51 percent in cases detected by PCR tests. For children 2 to 6 years of age, he reduced symptomatic cases by 35.7 percent and cases detected by PCR by 37 percent.

Რa is the following: Pfizer expects to complete the FDA submission this week, the release said. The FDA will schedule an advisory committee meeting to consider companies’s application when they complete their submission of data.

Pfizer, BioNTech Report 80% Efficacy of Covid-19 Vaccine for Younger Children

Source link Pfizer, BioNTech Report 80% Efficacy of Covid-19 Vaccine for Younger Children

Back to top button